CytomX Therapeutics Awarded Two Federal Research Grants under the Qualifying Therapeutic Discovery Project (QTDP) Program

SANTA BARBARA, Calif.--(BUSINESS WIRE)--CytomX Therapeutics, a biotechnology company focused on the development of proteolytically activated antibodies, today announced the receipt of two grants totaling more than $488,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program. The grants are directed toward the company’s lead preclinical programs targeting colon, head and neck, pancreatic and triple-negative breast cancers and glioblastoma multiforme (GBM).